These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 25186040)
1. Patient priority in the era of patent expiries. The Lancet Oncology Lancet Oncol; 2014 Sep; 15(10):1039. PubMed ID: 25186040 [No Abstract] [Full Text] [Related]
2. Patient priority in the era of patent expiries. Horning S Lancet Oncol; 2014 Oct; 15(11):e474. PubMed ID: 25281466 [No Abstract] [Full Text] [Related]
4. Why using Avastin for eye disease is so difficult. Torjesen I BMJ; 2012 May; 344():e3012. PubMed ID: 22549057 [No Abstract] [Full Text] [Related]
5. HER2 testing: the patent "genee" is out of the bottle. Goldman B CMAJ; 2007 May; 176(10):1443-4. PubMed ID: 17485697 [No Abstract] [Full Text] [Related]
6. NICE says drug for metastatic breast cancer is unaffordable for NHS. Kmietowicz Z BMJ; 2014 Apr; 348():g2888. PubMed ID: 24759923 [No Abstract] [Full Text] [Related]
7. FDA panel votes to pull Avastin in breast cancer, again. Ratner M Nat Biotechnol; 2011 Aug; 29(8):676. PubMed ID: 21822226 [No Abstract] [Full Text] [Related]
8. Funding of patients' groups. Slevin M Lancet; 2006 Jul; 368(9531):202. PubMed ID: 16844488 [No Abstract] [Full Text] [Related]
9. Pertuzumab to bolster Roche/Genentech's breast cancer franchise? Sheridan C Nat Biotechnol; 2011 Oct; 29(10):856-8. PubMed ID: 21997616 [No Abstract] [Full Text] [Related]
11. How much is more life worth? Brock DW Hastings Cent Rep; 2006; 36(3):17-9. PubMed ID: 16776018 [No Abstract] [Full Text] [Related]
12. Biosimilars lining up to compete with Herceptin--opportunity knocks. Nelson KM; Gallagher PC Expert Opin Ther Pat; 2014 Nov; 24(11):1149-53. PubMed ID: 25307085 [TBL] [Abstract][Full Text] [Related]
13. The ranibizumab saga of drug profiteering. Lee AC; Radford J BMJ; 2008 Sep; 337():a1532. PubMed ID: 18768564 [No Abstract] [Full Text] [Related]
14. [From orthoclone to denosumab, the fast growing market of monoclonal antibodies]. Biot J; Fasano C; Dos Santos C Med Sci (Paris); 2009 Dec; 25(12):1177-82. PubMed ID: 20035702 [TBL] [Abstract][Full Text] [Related]
15. Roche's decision to drop Herceptin patent in India opens way for generics. Limb M BMJ; 2013 Aug; 347():f5197. PubMed ID: 23959293 [No Abstract] [Full Text] [Related]
16. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis. Nerich V; Chelly J; Montcuquet P; Chaigneau L; Villanueva C; Fiteni F; Meneveau N; Perrin S; Voidey A; Monnot T; Pivot X; Limat S J Oncol Pharm Pract; 2014 Oct; 20(5):362-8. PubMed ID: 24158979 [TBL] [Abstract][Full Text] [Related]
17. Drug firms lose patent rights lawsuit against South Africa's government. Baleta A Lancet; 2001 Apr; 357(9265):1347. PubMed ID: 11343755 [No Abstract] [Full Text] [Related]
18. First biosimilar drug set to enter US market. Ledford H Nature; 2015 Jan; 517(7534):253-4. PubMed ID: 25592512 [No Abstract] [Full Text] [Related]
19. Ranibizumab: reject such high (exorbitant) prices. Prescrire Int; 2015 Sep; 24(163):205. PubMed ID: 26417626 [No Abstract] [Full Text] [Related]
20. Should the patent system for new medicines be abolished? DiMasi JA; Grabowski HG Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100 [No Abstract] [Full Text] [Related] [Next] [New Search]